FeNo coverage set for boost as reimbursement policy is revised in the US

Aerocrine has welcomed the decision by the BlueCross BlueShield of Minnesota to revise its previous negative coverage policy regarding Fractional exhaled Nitric Oxide (FeNO) testing, meaning that exhaled nitric oxide measurement will now be covered for patients with asthma. BlueCross is the largest insurance company in the state and provides coverage to approximately 66 per cent of the privately insured or nearly 1.8 million users. With this and other recent private payer coverage changes, more than 82 per cent of people in Minnesota will have coverage for FeNO testing.

This article is tagged to:
Sector: Medical Devices
Geography: Sweden

Enter your details to read the full article

By submitting this form you are acknowledging that you have read and understood our Privacy Policy.